SCHEDULE: Armistice Capital Exits Cyclacel Pharmaceuticals

Armistice Capital, LLC and Steven Boyd have reported a complete divestment of their beneficial ownership in Cyclacel Pharmaceuticals, Inc., now holding 0% of common stock.

Summary

• Armistice Capital, LLC and Steven Boyd, the Reporting Persons, no longer beneficially own any shares of Cyclacel Pharmaceuticals, Inc.
• Their aggregate beneficial ownership is 0 shares, representing 0% of the common stock.
• This filing is an Amendment No. 3 to their Schedule 13G, indicating a complete exit from their previous position.
• The percentage of shares is based on 1,583,965 shares outstanding as of July 10, 2025, as reported on the Issuer's Form S-1 filed on July 31, 2025.

Sentiment

Score: 2

Explanation: The complete divestment by a significant institutional investor is a strong negative signal, indicating a loss of confidence or a strategic exit from the company's stock.

Negatives

• A significant institutional investor, Armistice Capital, LLC, and its managing member, Steven Boyd, have fully divested their position in Cyclacel Pharmaceuticals, Inc.
• The complete exit of a beneficial owner can signal a lack of confidence in the company's future prospects or a shift in investment strategy.

Risks

• Potential negative market reaction due to a major institutional investor's complete divestment.
• Reduced institutional support for the company's stock.

Future Outlook

NA

Industry Context

The exit of a significant investor like Armistice Capital could be a concern, especially for a pharmaceutical company which often relies on investor confidence for R&D funding and clinical trial progress. It might suggest a re-evaluation of the company's pipeline or market position by institutional investors.

Stakeholder Impact

• Shareholders: Existing shareholders may face downward pressure on stock price due to the divestment and potential loss of institutional support.
• Potential Investors: May view the company less favorably given the exit of a notable investor.

Key Dates

Recommendation

The complete divestment by a significant institutional investor like Armistice Capital, as indicated by their 0% beneficial ownership in this Amendment No. 3 filing, is a strong negative signal. This suggests a lack of confidence in Cyclacel Pharmaceuticals, Inc.'s future prospects or a strategic decision to exit the investment entirely. Such an exit can lead to significant selling pressure and a decline in share price, making it a strong sell signal for investors.

Keywords

Cyclacel Pharmaceuticals, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, divestment, institutional investor, common stock, SEC filing